Casdin Capital

About Casdin Capital

Casdin Capital is a venture capital firm that specializes in investments across several key areas of the life sciences and healthcare sectors. Formed in 2011 and based in New York, New York, they focus on disruptive businesses that drive the life sciences revolution. With a deep commitment to the sectors they invest in, Casdin Capital supports endeavors in biotechnology, synthetic biology, healthcare, molecular medicine, and technology related to life sciences. They have a minimum investment of $100,000 and a maximum of $5,000,000, with a sweet spot of $1,500,000, targeting early-stage companies, particularly seed and Series A rounds. With over $2.23 billion in assets under management, they are notable players in the field with experience and expertise. Their philosophy encompasses investing in great ideas and teams, staying focused, and building strong relationships—all aimed at achieving big market impacts. Casdin Capital is actively engaged in sectors such as Healthcare Providers, Services, and Payers; Biotechnology including Life Science Tools, Diagnostics, and Drug Developers; and Synthetic Biology with applications in Agriculture, Livestock Management, and Specialty Chemicals. Furthermore, they invest in Technology capturing, storing, and processing data critical to advancing precision medicine. Their team upholds values such as Farsightedness, Knowledge, Reflectiveness, Consistency, Discipline, Engagement, and Principle adherence. They partner with companies that are revolutionizing the molecular understanding of life, driving data-based innovation in healthcare with efficiency and effectiveness. The fund prides itself on its seasoned expertise at the intersection of science and investment, supporting companies like 23andMe, 4D Molecular Therapeutics, A2 Biotherapeutics, and others with transformative potential in life sciences.